## Clinical Scenario A patient on antithyroid therapy develops a rash—a common adverse effect. The absence of fever, systemic symptoms, and hepatic dysfunction suggests a **drug rash** rather than severe hypersensitivity or hepatotoxicity. ## Management of Antithyroid Drug Rash **Key Point:** A rash during antithyroid therapy is an indication to **switch to the alternative antithyroid drug** (PTU ↔ methimazole). Cross-reactivity is uncommon (~25–30%), allowing safe substitution. **High-Yield:** Antithyroid drug adverse effects and their management: | Adverse Effect | Severity | Management | |---|---|---| | Rash (maculopapular) | Mild–moderate | Switch to alternative antithyroid drug | | Agranulocytosis | **Severe** | Discontinue immediately; no rechallenge | | Hepatitis / jaundice | Moderate–severe | Discontinue; consider radioiodine/surgery | | Vasculitis / ANCA-positive | Severe | Discontinue; systemic corticosteroids | | Pruritus alone | Mild | May continue with antihistamine | **Clinical Pearl:** PTU and methimazole have different chemical structures; cross-reactivity in rash is only ~25–30%. Therefore, switching is a rational first step before abandoning medical therapy entirely. ## Why NOT Continue the Same Drug? - Rash may worsen or progress to Stevens–Johnson syndrome or toxic epidermal necrolysis (rare but serious) - Patient compliance decreases with persistent rash - No evidence that antihistamines prevent progression of drug hypersensitivity ## Why NOT Discontinue All Drugs? - Premature escalation to radioiodine or surgery when a simple switch may succeed - Patient loses weeks of antithyroid control during the referral and treatment process - Radioiodine carries long-term hypothyroidism risk; surgery carries operative risk ## Why NOT Reduce Dose? - Dose reduction does not address the underlying hypersensitivity mechanism - Rash is not dose-dependent; it reflects immune sensitization - Lower doses may be inadequate to control thyroid hormone synthesis **Mnemonic:** **RASH = Reassign to Alternative antithyroid drug (Switch)** ## Follow-up - Start methimazole (or PTU if patient was on methimazole) at standard induction dose (20–30 mg/day) - Monitor rash resolution over 1–2 weeks - If rash persists or worsens on the alternative drug → consider radioiodine or thyroidectomy - If agranulocytosis, hepatitis, or vasculitis develops → discontinue immediately; no rechallenge [cite:Harrison 21e Ch 397; KD Tripathi 8e Ch 57]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.